Tsukasa Seya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2781906/publications.pdf

Version: 2024-02-01

		20817	2	3533
178	13,519	60		111
papers	citations	h-index		g-index
183	183	183		14640
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	TICAM-1, an adaptor molecule that participates in Toll-like receptor 3–mediated interferon-β induction. Nature Immunology, 2003, 4, 161-167.	14.5	1,107
2	Subcellular Localization of Toll-Like Receptor 3 in Human Dendritic Cells. Journal of Immunology, 2003, 171, 3154-3162.	0.8	646
3	TLR3: Interferon induction by double-stranded RNA including poly(I:C)â~†. Advanced Drug Delivery Reviews, 2008, 60, 805-812.	13.7	557
4	Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	27.8	536
5	Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochemical and Biophysical Research Communications, 2002, 293, 1364-1369.	2.1	411
6	Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium bovis Bacillus Calmette-Guelrin: Involvement of Toll-Like Receptors. Infection and Immunity, 2000, 68, 6883-6890.	2.2	381
7	TIR-containing Adapter Molecule (TICAM)-2, a Bridging Adapter Recruiting to Toll-like Receptor 4 TICAM-1 That Induces Interferon-1². Journal of Biological Chemistry, 2003, 278, 49751-49762.	3.4	345
8	Teleost TLR22 Recognizes RNA Duplex to Induce IFN and Protect Cells from Birnaviruses. Journal of Immunology, 2008, 181, 3474-3485.	0.8	319
9	Riplet/RNF135, a RING Finger Protein, Ubiquitinates RIG-I to Promote Interferon-β Induction during the Early Phase of Viral Infection. Journal of Biological Chemistry, 2009, 284, 807-817.	3.4	308
10	Prediction of the prototype of the human Toll-like receptor gene family from the pufferfish, Fugu rubripes, genome. Immunogenetics, 2003, 54, 791-800.	2.4	285
11	Epstein-Barr virus (EBV)–encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3. Journal of Experimental Medicine, 2009, 206, 2091-2099.	8.5	265
12	DDX60, a DEXD/H Box Helicase, Is a Novel Antiviral Factor Promoting RIG-I-Like Receptor-Mediated Signaling. Molecular and Cellular Biology, 2011, 31, 3802-3819.	2.3	232
13	Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway. Journal of Immunology, 2008, 180, 7175-7183.	0.8	228
14	The Ubiquitin Ligase Riplet Is Essential for RIG-I-Dependent Innate Immune Responses to RNA Virus Infection. Cell Host and Microbe, 2010, 8, 496-509.	11.0	218
15	Activation of the human innate immune system by Spirulina: augmentation of interferon production and NK cytotoxicity by oral administration of hot water extract of Spirulina platensis. International Immunopharmacology, 2002, 2, 423-434.	3.8	207
16	DEAD/H BOX 3 (DDX3) helicase binds the RIGâ€i adaptor IPSâ€i to upâ€regulate IFNâ€i²â€inducing potential. European Journal of Immunology, 2010, 40, 940-948.	2.9	196
17	Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2066-2071.	7.1	195
18	A Distinct Role of Riplet-Mediated K63-Linked Polyubiquitination of the RIG-I Repressor Domain in Human Antiviral Innate Immune Responses. PLoS Pathogens, 2013, 9, e1003533.	4.7	186

#	Article	IF	Citations
19	Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 252-257.	7.1	177
20	Tollâ€Like Receptor 3: A Link between Tollâ€Like Receptor, Interferon and Viruses. Microbiology and Immunology, 2004, 48, 147-154.	1.4	165
21	The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. International Immunology, 2004, 16, 1143-1154.	4.0	159
22	Simultaneous Blocking of Human Toll-Like Receptors 2 and 4 Suppresses Myeloid Dendritic Cell Activation Induced by Mycobacterium bovis Bacillus Calmette-Guelrin Peptidoglycan. Infection and Immunity, 2003, 71, 4238-4249.	2.2	154
23	Extracellular Vesicles Including Exosomes Regulate Innate Immune Responses to Hepatitis B Virus Infection. Frontiers in Immunology, 2016, 7, 335.	4.8	152
24	Molecular Cloning and Functional Characterization of Chicken Toll-like Receptors. Journal of Biological Chemistry, 2001, 276, 47143-47149.	3.4	149
25	Antiviral responses induced by the TLR3 pathway. Reviews in Medical Virology, 2011, 21, 67-77.	8.3	132
26	DDX60 Is Involved in RIG-I-Dependent and Independent Antiviral Responses, and Its Function Is Attenuated by Virus-Induced EGFR Activation. Cell Reports, 2015, 11, 1193-1207.	6.4	127
27	NAK-Associated Protein 1 Participates in Both the TLR3 and the Cytoplasmic Pathways in Type I IFN Induction. Journal of Immunology, 2006, 177, 8676-8683.	0.8	124
28	Cutting Edge: NF-κB-Activating Kinase-Associated Protein 1 Participates in TLR3/Toll-IL-1 Homology Domain-Containing Adapter Molecule-1-Mediated IFN Regulatory Factor 3 Activation. Journal of Immunology, 2005, 174, 27-30.	0.8	123
29	Phylogenetic and expression analysis of amphibian Xenopus Toll-like receptors. Immunogenetics, 2007, 59, 281-293.	2.4	118
30	<i>Mycoplasma fermentans</i> Lipoprotein M161Ag-Induced Cell Activation Is Mediated by Toll-Like Receptor 2: Role of N-Terminal Hydrophobic Portion in its Multiple Functions. Journal of Immunology, 2001, 166, 2610-2616.	0.8	115
31	Differential Type I IFN-Inducing Abilities of Wild-Type versus Vaccine Strains of Measles Virus. Journal of Immunology, 2007, 179, 6123-6133.	0.8	112
32	Development of immunoadjuvants for immunotherapy of cancer. International Immunopharmacology, 2001, 1, 1249-1259.	3.8	108
33	Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nature Communications, 2015, 6, 6280.	12.8	107
34	Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. Nature Communications, 2013, 4, 1833.	12.8	106
35	Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice. Cancer Research, 2004, 64, 757-764.	0.9	104
36	Surface-Expressed TLR6 Participates in the Recognition of Diacylated Lipopeptide and Peptidoglycan in Human Cells. Journal of Immunology, 2005, 174, 1566-1573.	0.8	104

3

#	Article	IF	CITATIONS
37	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports, 2017, 19, 1874-1887.	6.4	104
38	Dendritic Cell Maturation Induced by Muramyl Dipeptide (MDP) Derivatives: Monoacylated MDP Confers TLR2/TLR4 Activation. Journal of Immunology, 2005, 174, 7096-7103.	0.8	96
39	Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochemical and Biophysical Research Communications, 2003, 311, 39-48.	2.1	92
40	Combinational recognition of bacterial lipoproteins and peptidoglycan by chicken Toll-like receptor 2 subfamily. Developmental and Comparative Immunology, 2008, 32, 147-155.	2.3	89
41	Identification of a polyl:C-inducible membrane protein that participates in dendritic cell–mediated natural killer cell activation. Journal of Experimental Medicine, 2010, 207, 2675-2687.	8.5	89
42	Phylogenetic and expression analysis of lamprey toll-like receptors. Developmental and Comparative Immunology, 2010, 34, 855-865.	2.3	84
43	Spatiotemporal Mobilization of Toll/IL-1 Receptor Domain-Containing Adaptor Molecule-1 in Response to dsRNA. Journal of Immunology, 2007, 179, 6867-6872.	0.8	82
44	Interferon- \hat{l}^2 Induction Through Toll-Like Receptor 3 Depends on Double-Stranded RNA Structure. DNA and Cell Biology, 2005, 24, 614-623.	1.9	80
45	Hepatitis C Virus Core Protein Abrogates the DDX3 Function That Enhances IPS-1-Mediated IFN–Beta Induction. PLoS ONE, 2010, 5, e14258.	2.5	80
46	Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Molecular Immunology, 2010, 47, 1283-1291.	2.2	80
47	The TLR3/TICAM-1 Pathway Is Mandatory for Innate Immune Responses to Poliovirus Infection. Journal of Immunology, 2011, 187, 5320-5327.	0.8	80
48	Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Research, 2003, 23, 4369-76.	1,1	80
49	Hepatitis C virus–infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology, 2008, 48, 48-58.	7.3	79
50	Polyl:C–Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector–Mediated Tumor Elimination <i>In Vivo</i> . Cancer Immunology Research, 2015, 3, 902-914.	3.4	79
51	Raftlin Is Involved in the Nucleocapture Complex to Induce Poly(I:C)-mediated TLR3 Activation. Journal of Biological Chemistry, 2011, 286, 10702-10711.	3.4	7 5
52	The Clathrin-Mediated Endocytic Pathway Participates in dsRNA-Induced IFN-Î ² Production. Journal of Immunology, 2008, 181, 5522-5529.	0.8	73
53	Mycobacterium bovis BCG Cell Wall-Specific Differentially Expressed Genes Identified by Differential Display and cDNA Subtraction in Human Macrophages. Infection and Immunity, 2004, 72, 937-948.	2.2	71
54	Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. International Immunology, 2007, 19, 1145-1155.	4.0	70

#	Article	IF	CITATIONS
55	Functional evolution of the TICAMâ€1 pathway for extrinsic RNA sensing. Immunological Reviews, 2009, 227, 44-53.	6.0	70
56	Pan-Vertebrate Toll-Like Receptors During Evolution. Current Genomics, 2008, 9, 488-493.	1.6	69
57	STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation. Biochemical and Biophysical Research Communications, 2016, 478, 1764-1771.	2.1	66
58	Lamprey TLRs with Properties Distinct from Those of the Variable Lymphocyte Receptors. Journal of Immunology, 2007, 178, 397-406.	0.8	65
59	Homo-oligomerization Is Essential for Toll/Interleukin-1 Receptor Domain-containing Adaptor Molecule-1-mediated NF-κB and Interferon Regulatory Factor-3 Activation. Journal of Biological Chemistry, 2008, 283, 18283-18291.	3.4	63
60	Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I. Journal of Biochemistry, 2012, 151, 5-11.	1.7	62
61	Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice. Cancer Science, 2009, 100, 1494-1501.	3.9	61
62	Adjuvant for vaccine immunotherapy of cancer – focusing on Tollâ€like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Science, 2015, 106, 1659-1668.	3.9	61
63	Wild-Type Measles Virus Infection in Human CD46/CD150-Transgenic Mice: CD11c-Positive Dendritic Cells Establish Systemic Viral Infection. Journal of Immunology, 2005, 175, 3252-3261.	0.8	58
64	Cross-priming for antitumor CTL induced by soluble Ag + polyl:C depends on the TICAM-1 pathway in mouse CD11c ⁺ /CD8î± ⁺ dendritic cells. Oncolmmunology, 2012, 1, 581-592.	4.6	58
65	Accessory Factors of Cytoplasmic Viral RNA Sensors Required for Antiviral Innate Immune Response. Frontiers in Immunology, 2016, 7, 200.	4.8	58
66	A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2. International Journal of Biochemistry and Cell Biology, 2002, 34, 901-906.	2.8	57
67	Role of Toll-like Receptors in Adjuvant-Augmented Immune Therapies. Evidence-based Complementary and Alternative Medicine, 2006, 3, 31-38.	1.2	57
68	TLR2-Dependent Induction of IL-10 and Foxp3+CD25+CD4+ Regulatory T Cells Prevents Effective Anti-Tumor Immunity Induced by Pam2 Lipopeptides In Vivo. PLoS ONE, 2011, 6, e18833.	2.5	57
69	Beyond dsRNA: Toll-like receptor 3 signalling in RNA-induced immune responses. Biochemical Journal, 2014, 458, 195-201.	3.7	56
70	Toll-like receptor-mediated tyrosine phosphorylation of paxillin via MyD88-dependent and -independent pathways. European Journal of Immunology, 2003, 33, 740-747.	2.9	55
71	Structures and interface mapping of the TIR domain-containing adaptor molecules involved in interferon signaling. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19908-19913.	7.1	55
72	Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1897.	4.8	55

#	Article	IF	Citations
73	Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants. Journal of Innate Immunity, 2018, 10, 515-521.	3.8	55
74	The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunology, Immunotherapy, 2009, 58, 1175-1184.	4.2	54
75	TICAM-1 and TICAM-2: toll-like receptor adapters that participate in induction of type 1 interferons. International Journal of Biochemistry and Cell Biology, 2005, 37, 524-529.	2.8	52
76	Toll-like receptor 2 ligand and interferon- \hat{l}^3 suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. Oncolmmunology, 2018, 7, e1373231.	4.6	52
77	The Peptide Sequence of Diacyl Lipopeptides Determines Dendritic Cell TLR2-Mediated NK Activation. PLoS ONE, 2010, 5, e12550.	2.5	49
78	Recognition of Viral RNA by Pattern Recognition Receptors in the Induction of Innate Immunity and Excessive Inflammation During Respiratory Viral Infections. Viral Immunology, 2017, 30, 408-420.	1.3	47
79	TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis. Oncolmmunology, 2012, 1, 917-923.	4.6	46
80	Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification. Microbes and Infection, 2002, 4, 785-794.	1.9	44
81	Raftlin Controls Lipopolysaccharide-Induced TLR4 Internalization and TICAM-1 Signaling in a Cell Type–Specific Manner. Journal of Immunology, 2016, 196, 3865-3876.	0.8	43
82	A Molecular Mechanism for Toll-IL-1 Receptor Domain-containing Adaptor Molecule-1-mediated IRF-3 Activation. Journal of Biological Chemistry, 2010, 285, 20128-20136.	3.4	42
83	Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncolmmunology, 2016, 5, e1188244.	4.6	41
84	Pattern recognition receptors of innate immunity and their application to tumor immunotherapy. Cancer Science, 2010, 101, 313-320.	3.9	38
85	Cell Type-Specific Subcellular Localization of Phospho-TBK1 in Response to Cytoplasmic Viral DNA. PLoS ONE, 2013, 8, e83639.	2.5	37
86	A novel protein that participates in nonself discrimination of malignant cells by homologous complement. Nature Medicine, 1997, 3, 1266-1270.	30.7	35
87	Myeloid-Derived Suppressor Cells Confer Tumor-Suppressive Functions on Natural Killer Cells via Polyinosinic:Polycytidylic Acid Treatment in Mouse Tumor Models. Journal of Innate Immunity, 2014, 6, 293-305.	3.8	35
88	Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochemical and Biophysical Research Communications, 2015, 457, 445-450.	2.1	35
89	Functional interfaces between TICAM-2/TRAM and TICAM-1/TRIF in TLR4 signaling. Biochemical Society Transactions, 2017, 45, 929-935.	3.4	35
90	Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: A case-control study. Surgery Today, 2009, 39, 194-200.	1.5	33

#	Article	IF	Citations
91	LRRC59 Regulates Trafficking of Nucleic Acid–Sensing TLRs from the Endoplasmic Reticulum via Association with UNC93B1. Journal of Immunology, 2015, 195, 4933-4942.	0.8	33
92	INAM Plays a Critical Role in IFN-γ Production by NK Cells Interacting with Polyinosinic-Polycytidylic Acid–Stimulated Accessory Cells. Journal of Immunology, 2014, 193, 5199-5207.	0.8	31
93	Structural and Functional Properties of Complement-activating Protein M161Ag, a Mycoplasma fermentans Gene Product That Induces Cytokine Production by Human Monocytes. Journal of Biological Chemistry, 1998, 273, 12407-12414.	3.4	30
94	Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers. Hepatology International, 2008, 2, 222-230.	4.2	30
95	Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-β-inducing potential. Molecular Immunology, 2011, 48, 497-504.	2.2	30
96	Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV <i>in vitro</i> i>and <i>in vivo</i> i>. Oncotarget, 2016, 7, 68179-68193.	1.8	30
97	HTLV-1 Tax Induces Formation of the Active Macromolecular IKK Complex by Generating Lys63- and Met1-Linked Hybrid Polyubiquitin Chains. PLoS Pathogens, 2017, 13, e1006162.	4.7	30
98	A Short Consensus Repeat-Containing Complement Regulatory Protein of Lamprey That Participates in Cleavage of Lamprey Complement 3. Journal of Immunology, 2004, 173, 1118-1128.	0.8	29
99	Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Letters, 2007, 581, 3334-3340.	2.8	29
100	A Novel Chicken Membrane-Associated Complement Regulatory Protein: Molecular Cloning and Functional Characterization. Journal of Immunology, 2001, 166, 424-431.	0.8	28
101	Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway. Cell Death and Differentiation, 2017, 24, 385-396.	11.2	28
102	Tollâ€like receptor 3 signal augments radiationâ€induced tumor growth retardation in a murine model. Cancer Science, 2018, 109, 956-965.	3.9	26
103	A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy. Advanced Drug Delivery Reviews, 2019, 147, 37-43.	13.7	26
104	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes and Infection, 2011, 13, 350-358.	1.9	25
105	Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2018, 94, 153-160.	3.8	25
106	Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 533-544.	3.4	24
107	High Levels of RAE-1 Isoforms on Mouse Tumor Cell Lines Assessed by Anti-"pan―RAE-1 Antibody Confer Tumor Susceptibility to NK Cells. Biochemical and Biophysical Research Communications, 2002, 290, 140-145.	2.1	22
108	Vaccine immunotherapy with ARNAX induces tumorâ€specific memory T cells and durable antiâ€tumor immunity in mouse models. Cancer Science, 2018, 109, 2119-2129.	3.9	22

#	Article	IF	Citations
109	Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy. Journal of Experimental and Clinical Cancer Research, 2016, 35, 143.	8.6	21
110	The Anti-Oxidant Ergothioneine Augments the Immunomodulatory Function of TLR Agonists by Direct Action on Macrophages. PLoS ONE, 2017, 12, e0169360.	2.5	21
111	Molecular cloning and functional characterization of guinea pig IL-12. International Immunology, 2001, 13, 1129-1139.	4.0	20
112	Lipopeptides from <i>Staphylococcus aureus</i> as Tlr2 Ligands: Prediction with mRNA Expression, Chemical Synthesis, and Immunostimulatory Activities. ChemBioChem, 2009, 10, 2311-2315.	2.6	20
113	Development of Mouse Hepatocyte Lines Permissive for Hepatitis C Virus (HCV). PLoS ONE, 2011, 6, e21284.	2.5	20
114	14-3-3-zeta participates in TLR3-mediated TICAM-1 signal-platform formation. Molecular Immunology, 2016, 73, 60-68.	2.2	20
115	Ligation of Human CD46 with Purified Complement C3b or F(ab)of Monoclonal Antibodies Enhances Isoform-Specific Interferon Gamma-Dependent Nitric Oxide Production in Macrophages. Journal of Biochemistry, 2002, 132, 83-91.	1.7	19
116	Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Science, 2010, 101, 1596-1603.	3.9	19
117	Natural Killer Cell Activation Secondary to Innate Pattern Sensing. Journal of Innate Immunity, 2011, 3, 264-273.	3.8	19
118	Assessment of the Toll-Like Receptor 3 Pathway in Endosomal Signaling. Methods in Enzymology, 2014, 535, 149-165.	1.0	19
119	Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 937-946.	3.1	19
120	Antibodies against human Toll-like receptors (TLRs): TLR distribution and localization in human dendritic cells. Journal of Endotoxin Research, 2005, 11, 369-374.	2.5	18
121	Regulator of Complement Activation (RCA) Locus in Chicken: Identification of Chicken RCA Gene Cluster and Functional RCA Proteins. Journal of Immunology, 2005, 175, 1724-1734.	0.8	18
122	TAMable tumor-associated macrophages in response to innate RNA sensing. Oncolmmunology, 2012, 1, 1000-1001.	4.6	18
123	The MyD88 Pathway in Plasmacytoid and CD4+Dendritic Cells Primarily Triggers Type I IFN Production against Measles Virus in a Mouse Infection Model. Journal of Immunology, 2013, 191, 4740-4747.	0.8	18
124	IPS-1 Is Essential for Type III IFN Production by Hepatocytes and Dendritic Cells in Response to Hepatitis C Virus Infection. Journal of Immunology, 2014, 192, 2770-2777.	0.8	18
125	The Kinase Complex Responsible for IRF-3–Mediated IFN-β Production in Myeloid Dendritic Cells (mDC). Journal of Biochemistry, 2006, 139, 171-175.	1.7	17
126	Development of mouse models for analysis of human virus infections. Microbiology and Immunology, 2017, 61, 107-113.	1.4	16

#	Article	IF	Citations
127	Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. Frontiers in Immunology, 2018, 9, 496.	4.8	16
128	A MAVS/TICAM-1-Independent Interferon-Inducing Pathway Contributes to Regulation of Hepatitis B Virus Replication in the Mouse Hydrodynamic Injection Model. Journal of Innate Immunity, 2015, 7, 47-58.	3.8	15
129	Measles virus hemagglutinin triggers intracellular signaling in CD150-expressing dendritic cells and inhibits immune response. Cellular and Molecular Immunology, 2016, 13, 828-838.	10.5	15
130	Zyxin stabilizes RIG-I and MAVS interactions and promotes type I interferon response. Scientific Reports, 2017, 7, 11905.	3.3	15
131	An Alternative Form of IL-18 in Human Blood Plasma: Complex Formation with IgM Defined by Monoclonal Antibodies. Journal of Immunology, 2001, 166, 6671-6679.	0.8	14
132	Regulator of complement activation (RCA) gene cluster in Xenopus tropicalis. Immunogenetics, 2009, 61, 371-384.	2.4	14
133	Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV). Sensors, 2015, 15, 27160-27173.	3.8	14
134	Dendritic cell subsets involved in type I IFN induction in mouse measles virus infection models. International Journal of Biochemistry and Cell Biology, 2014, 53, 329-333.	2.8	13
135	Evolution of the DEAD box helicase family in chicken: chickens have no DHX9 ortholog. Microbiology and Immunology, 2015, 59, 633-640.	1.4	13
136	cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue. Medical Sciences (Basel, Switzerland), 2017, 5, 35.	2.9	13
137	Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy. Frontiers in Immunology, 2019, 10, 671.	4.8	13
138	Complement Activation in Mycoplasma fermentans -Induced Mycoplasma Clearance from Infected Cells: Probing of the Organism with Monoclonal Antibodies against M161Ag. Infection and Immunity, 2000, 68, 1672-1680.	2.2	12
139	Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia. Oncolmmunology, 2016, 5, e1043506.	4.6	12
140	Human Macrophages Produce Dimeric Forms of IL-18 Which Can Be Detected with Monoclonal Antibodies Specific for Inactive IL-18. Biochemical and Biophysical Research Communications, 2001, 281, 461-467.	2.1	11
141	Recombinant interleukin-12 and interleukin-18 antitumor therapy in a guinea-pig hepatoma cell implant model. Cancer Science, 2007, 98, 1936-1942.	3.9	11
142	Multi-Step Regulation of Interferon Induction by Hepatitis C Virus. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 127-138.	2.3	10
143	Toll-IL-1-Receptor-Containing Adaptor Molecule-1. Progress in Molecular Biology and Translational Science, 2013, 117, 487-510.	1.7	10
144	Live imaging of transforming growth factor $\hat{a} \in \hat{l}^2$ activated kinase 1 activation in Lewis lung carcinoma 3 < scp > LL < / scp > cells implanted into syngeneic mice and treated with polyinosinic:polycytidylic acid. Cancer Science, 2016, 107, 644-652.	3.9	10

#	Article	IF	CITATIONS
145	Oligomerized TICAMâ€1 (TRIF) in the cytoplasm recruits nuclear BS69 to enhance NFâ€PB activation and type I IFN induction. European Journal of Immunology, 2009, 39, 3469-3476.	2.9	9
146	Tumor cell death by pattern-sensing of exogenous RNA: Tumor cell TLR3 directly induces necroptosis by poly(I:C) in vivo, independent of immune effector-mediated tumor shrinkage. Oncolmmunology, 2017, 6, e1078968.	4.6	9
147	Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination. Biochemical and Biophysical Research Communications, 2018, 506, 1019-1025.	2.1	9
148	A possible abscopal effect of post-irradiation immunotherapy in two patients with metastatic lung tumors. International Cancer Conference Journal, 2014, 3, 122-127.	0.5	8
149	The second and third amino acids of Pam2 lipopeptides are key for the proliferation of cytotoxic T cells. Innate Immunity, 2018, 24, 323-331.	2.4	8
150	Functional Alteration of Tumor-infiltrating Myeloid Cells in RNA Adjuvant Therapy. Anticancer Research, 2015, 35, 4385-92.	1.1	8
151	The N-terminal domain of TIR domain-containing adaptor molecule-1, TICAM-1. Journal of Biomolecular NMR, 2014, 58, 227-230.	2.8	7
152	Measles Virus Takes a Two-Pronged Attack on PP1. Cell Host and Microbe, 2014, 16, 1-2.	11.0	7
153	MAVS-dependent IRF3/7 bypass of interferon \hat{l}^2 -induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells. Molecular Immunology, 2014, 57, 100-110.	2.2	7
154	Nucleic Acid Sensors Involved in the Recognition of HBV in the Liver–Specific in vivo Transfection Mouse Models—Pattern Recognition Receptors and Sensors for HBV. Medical Sciences (Basel,) Tj ETQq0 0 0 rg/	BT2 !.© verlo	ck⊽10 Tf 50 3
155	Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome. Thrombosis Research, 2018, 164, 63-68.	1.7	7
156	TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cells. Biochemical and Biophysical Research Communications, 2018, 499, 985-991.	2.1	7
157	Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model. ImmunoHorizons, 2022, 6, 275-282.	1.8	7
158	The J6JFH1 Strain of Hepatitis C Virus Infects Human B-Cells with Low Replication Efficacy. Viral Immunology, 2014, 27, 285-294.	1.3	5
159	Identification of a Regulatory Acidic Motif as the Determinant of Membrane Localization of TICAM-2. Journal of Immunology, 2015, 195, 4456-4465.	0.8	5
160	Inhibition of lipid A-mediated type I interferon induction by Bactericidal/permeability-increasing protein (BPI). Biochemical and Biophysical Research Communications, 2007, 354, 574-578.	2.1	4
161	Addendum to "Strain-to-strain difference of V protein of measles virus affects MDA5-mediated IFN-β-inducing potential―[Mol. Immunol. 48(4) (2011) 497–504]. Molecular Immunology, 2011, 48, 1589-1590.	2.2	4
162	Double-stranded RNA analog and type I interferon regulate expression of Trem paired receptors in murine myeloid cells. BMC Immunology, 2016, 17, 9.	2.2	4

#	Article	lF	Citations
163	Innate immunity and vaccine. Vaccine, 2010, 28, 8041-8042.	3.8	3
164	PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Immunobiology, 2015, 220, 74-82.	1.9	3
165	Cytokine responses to eye spray adjuvants for enhancing vaccineâ€induced immunity in chickens. Microbiology and Immunology, 2016, 60, 511-515.	1.4	3
166	Cytoplasmic dsRNA induces the expression of OCT3/4 and NANOG mRNAs in differentiated human cells. Journal of Biological Chemistry, 2019, 294, 18969-18979.	3.4	3
167	RIOK3 keeps MDA5 inactive. Oncotarget, 2015, 6, 30423-30424.	1.8	3
168	HCV and innate immunity. Uirusu, 2008, 58, 19-26.	0.1	2
169	The TLR3/TICAM-1 signal constitutively controls spontaneous polyposis through suppression of c-Myc in Apc Min/+ mice. Journal of Biomedical Science, 2017, 24, 79.	7.0	2
170	The Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells., 2015,, 25-47.		2
171	Dendritic Cell/NK Cell Interaction in RNA Virus Infection. Current Immunology Reviews, 2009, 5, 200-207.	1.2	2
172	Development of monoclonal antibodies that specifically interact with necrotic lymphoma cells. Microbiology and Immunology, 2011, 55, 373-377.	1.4	1
173	Adjuvant Immunotherapy for Cancer: From Basic Research to Clinical Bench. , 2015, , 229-241.		1
174	The dataset of proteins specifically interacted with activated TICAM-1. Data in Brief, 2016, 8, 697-699.	1.0	1
175	Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy., 2016,, 235-246.		1
176	Toll-like receptor and pattern sensing for evoking immune responseâ [*] †. Advanced Drug Delivery Reviews, 2008, 60, 779-781.	13.7	0
177	Glycan Vaccine. , 2019, , 179-187.		0
178	Hepatitis B virus genomic nucleic acid in the activation and maturation of bone marrow-derived dendritic cells. Asia-Pacific Journal of Molecular Biology and Biotechnology, 0, , 109-119.	0.1	0